Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Thomas P. Plewman reported sales of common stock via Form 144. The filing lists multiple dispositions: 5,662 shares (sale proceeds $1,155,048.00) on 02/10/2026, 958 shares (proceeds $196,227.14) on 02/19/2026, and 410 shares (proceeds $85,169.30) on 03/03/2026. The excerpt also shows 2,855 shares from a restricted stock vesting entry dated 02/23/2026.
Quest Diagnostics executive Catherine T. Doherty reported sales and related share dispositions of company stock. On March 3, 2026, she executed an open-market sale of 632 shares of common stock at $207.73 per share, leaving 67,122 shares held directly.
On March 2, 2026, 648 shares were disposed of at $204.86 per share to cover tax obligations tied to the vesting of restricted share units, and the sale activity was carried out under a pre-arranged Rule 10b5-1 trading plan. She also holds 4,502 shares indirectly through a company 401(k)/profit sharing plan.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported a Form 4 transaction involving common stock. On the reported date, he disposed of 869 shares at $204.86 per share in a tax-withholding transaction tied to the vesting of a prior restricted stock unit grant. This was a sale of shares to satisfy tax obligations rather than an open-market trade. After this transaction, he directly owned 27,041 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president and general counsel Michael E. Prevoznik reported recent stock transactions. On March 3, he executed an open-market sale of 526 shares of common stock at $207.73 per share under a Rule 10b5-1 sales plan, leaving 37,557 shares held directly afterward. On March 2, 288 shares were disposed of at $204.86 per share to cover tax obligations from the vesting of restricted share units. He also has 5,737 shares held indirectly through company 401(k) and deferred compensation plans.
Quest Diagnostics CEO and President J. E. Davis reported two stock transactions in company common stock. He disposed of 2,968 shares at $204.86 per share to satisfy tax obligations from the vesting of a prior restricted share unit grant. He also completed an open-market sale of 10,000 shares at $212.52 per share under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 117,185 Quest Diagnostics shares.
Quest Diagnostics senior vice president Patrick Plewman reported two stock dispositions. He sold 410 shares of common stock in an open-market transaction at $207.73 per share under a Rule 10b5-1 sales plan he previously adopted.
He also disposed of 230 shares at $204.86 per share to cover tax obligations from the vesting of an earlier restricted share unit grant. After these transactions, he directly owns 15,198 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president Karthik Kuppusamy disposed of 205 shares of common stock at $204.86 per share to cover tax obligations from vesting restricted share units. This tax-withholding transaction on March 2, 2026 was not an open-market sale. After the transaction, he held 9,869 shares directly, plus additional indirect holdings through a trust and the company’s 401(k) plan.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported a small, automatic share disposition related to taxes. On the transaction date, 188 shares of common stock were withheld at a price of $204.86 per share to satisfy tax obligations from vesting restricted share units. After this tax-withholding event, Delaney directly owned 8,508 Quest Diagnostics common shares.
Quest Diagnostics senior executive reports small tax-related share disposition. Michael J. Deppe, SVP, Corporate Controller and Chief Accounting Officer of Quest Diagnostics, had 88 shares of common stock withheld at $204.86 per share on a Form 4 event dated March 2, 2026 to satisfy tax obligations from previously vested restricted share units, rather than an open-market sale. After this transaction, he directly held 34,473 shares of Quest Diagnostics common stock. The filing also notes indirect ownership of 706 shares through the company’s 401(k) Profit Sharing Plan, with balances based on plan administrator data.
Catherine T. Doherty reported sales of Common Stock under a Form 144 filing. The filing lists sales of $5,393,815.32 for 26,165 shares on 02/13/2026 and $293,521.39 for 1,433 shares on 02/19/2026.
The filing also shows 632 shares tied to restricted stock vesting dated 02/23/2026, identified as securities to be sold. The transactions are reported on a Form 144 related to Common shares.